The Canada-based cannabis company, Aurora Cannabis (NYSE:ACB) ,has struck a deal to enter the U.S. CBD market, with the company agreeing to pay a $2.5 million deposit, while the Department of Justice (DOJ) has granted its application to export cannabis products to the United States.
Aurora Cannabis (ACBFF) (NYSE:ACB) has announced plans to enter the U.S. market with a new subsidiary focused on the production, processing and distribution of hemp-based cannabidiol (CBD) products.
The cannabis market has exploded into a multi-billion dollar industry in the past few years, and Canadian cannabis company Aurora Cannabis (NYSE:ACB) is doing its part to get a piece of that pie. The company just announced a partnership with HempMeds to enter the legal U.S. CBD market. CBD (cannabidiol) is the non-psychoactive chemical compound that is found in cannabis, and is undergoing a lot of research in the medical community.
Marijuana operator Aurora Cannabis (NYSE:ACB) has announced that it has signed an agreement to acquire Reliva. Reliva is one of the largest sellers of cannabidiol (CBD) cannabis products in the United States. Aurora will enter the CBD market in the United States through its acquisition of Reliva. CBD is one of the components of cannabis, but unlike tetrahydrocannabinol (THC), which is found in large quantities in marijuana, it does not cause intoxication. The CBD market is a potential market that is expected to reach approximately $24 billion by 2025 in the United States . Reliva products containing hemp-derived CBD are currently available at more than 20,000 outlets in the United States. The acquisition agreement will be a pure equity transaction in which Aurora will transfer approximately $40 million of common stock to Reliva shareholders. In addition, the agreement includes a potential payment to of approximately $45 million in cash or additional Aurora shares or both. However, an additional amount will be paid if Reliva achieves certain financial milestones over the next two years. This is expected to minimize risk to Aurora shareholders and incentivize Reliva management to create significant value for the newly combined company. The companies will complete the transaction in June, subject to approval by ‘s shareholders and regulators. Acquisition of will help Aurora return to profitability For Aurora, this acquisition is a opportunity to increase revenue and achieve its goal of achieving positive adjusted EBITDA by FY1 2021. Interim CEO Michael Singer of said in a press release that the partnership will help create a leading cannabinoid business that can provide with strong growth in revenue and profitability. Singer added that Aurora has taken the time to evaluate ‘s entry into the growing US market, and that they are optimistic about the long-term benefits of a partnership with . He said Reliva will give an opportunity to grow globally in the cannabis-based CBD segment.Aurora Cannabis has made some significant headlines with its recent announcement that it is entering the U.S. CBD market, in partnership with hemp-derived CBD company MediSwipe, and has secured a supply of CBD oil to be supplied to MediSwipe for sale in the U.S.. Read more about yahoo finance and let us know what you think.
Frequently Asked Questions
Will Aurora stock bounce back?
Aurora Cannabis shares are up more than 50% since listing on the New York Stock Exchange in January, and they are now up more than 200% since listing in May, making it one of the best performing stocks in the entire cannabis sector. But that hasn’t stopped the chatter that the stock is overvalued now that it’s trading at more than 90 times earnings. Aurora Cannabis (ACB) stock is at an all-time high right now, and it’s not hard to see why. The Canadian grower’s recent acquisition of Pedanios, a German company that makes CBD products, has significantly boosted its business prospects in Europe and the U.S.
What is a CBD cannabis?
When it comes to marijuana, it is not just about the THC content. There are many other compounds in marijuana that play a role in its psychoactive effects. The two most well known, cannabinoids are tetrahydrocannabinol (THC) and cannabidiol (CBD). While the latter is not psychoactive in itself, it does affect the body in different ways than just staying in the blood system. Cannabis, for better or worse, has been making headlines in the past year. After all, it’s no longer a fringe product. On one hand, the idea of a legal cannabis market in the U.S. is a boon for the industry, but on the other, it raises a lot of questions and concerns. One of the biggest questions that’s been on many people’s minds relates to CBD, or cannabidiol, a non-psychoactive compound found in cannabis.
Is ACB a buy or sell?
The Company has announced a huge milestone, it has received a licence from Health Canada to sell its cannabis oil in the US. This is huge news since ACB is going to be the first company that is going to enter the US market over 10 years, with big name investors such as DCM Ventures and Aphria. After months of waiting, it seems that ACB stock may finally be able to capitalize on the U.S. marijuana market. The company announced that it has reached a deal with the U.S. based cannabis research firm, Steep Hill Lab to provide CBD products to the company’s supply chain. ACB stock has been trading higher since the announcement and is now sitting at $6.00 per share, a 20% gain from its intraday low.
Related Tags:
canopy growthacb stock splitaphaacb stock forecasttilrayaurora canada stock,People also search for,Feedback,Privacy settings,How Search works,Canopy Growth Corporation,Company,Canopy Growth,Tilray,Pharmaceutical company,Aurora Cannabis,Sundial Growers,GW Pharmace…,Constellati… Brands,HEXO,See more,acb stock split,apha,acb stock forecast,aurora canada stock,yahoo finance,canopy growth stock
